CN108969648B - Pharmaceutical composition and application method thereof - Google Patents
Pharmaceutical composition and application method thereof Download PDFInfo
- Publication number
- CN108969648B CN108969648B CN201810240486.4A CN201810240486A CN108969648B CN 108969648 B CN108969648 B CN 108969648B CN 201810240486 A CN201810240486 A CN 201810240486A CN 108969648 B CN108969648 B CN 108969648B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- mycoplasma pneumonia
- parts
- servings
- raw material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 31
- 238000000034 method Methods 0.000 title description 7
- 208000001572 Mycoplasma Pneumonia Diseases 0.000 claims abstract description 31
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 claims abstract description 31
- 239000002994 raw material Substances 0.000 claims abstract description 21
- 235000011437 Amygdalus communis Nutrition 0.000 claims abstract description 11
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 11
- 235000020224 almond Nutrition 0.000 claims abstract description 11
- 244000274050 Platycodon grandiflorum Species 0.000 claims abstract description 10
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims abstract description 10
- 244000248557 Ophiopogon japonicus Species 0.000 claims abstract 3
- 241000220304 Prunus dulcis Species 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims description 12
- 241001494479 Pecora Species 0.000 claims description 11
- 241000204003 Mycoplasmatales Species 0.000 claims description 10
- 241000605372 Fritillaria Species 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000469 ethanolic extract Substances 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 17
- 201000010099 disease Diseases 0.000 abstract description 16
- 241000935235 Fritillaria meleagris Species 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 description 16
- 230000000694 effects Effects 0.000 description 10
- 244000144972 livestock Species 0.000 description 10
- 206010011224 Cough Diseases 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 244000144725 Amygdalus communis Species 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 241000107360 Vincetoxicum glaucescens Species 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 201000004813 Bronchopneumonia Diseases 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- 240000002948 Ophiopogon intermedius Species 0.000 description 1
- 206010034107 Pasteurella infections Diseases 0.000 description 1
- 235000006751 Platycodon Nutrition 0.000 description 1
- 241000357613 Platycodon Species 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 201000005115 pasteurellosis Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229930189914 platycodon Natural products 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- UURAUHCOJAIIRQ-QGLSALSOSA-N tiamulin Chemical compound CCN(CC)CCSCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 UURAUHCOJAIIRQ-QGLSALSOSA-N 0.000 description 1
- 229960004885 tiamulin Drugs 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种药物组合物，该组合物包括以下按质量计的原料：金银花1~3份，贝母1~3份，桔梗1~3份，白前1~3份，杏仁1~3份，麦冬1~3份。本发明的药物组合物不仅能防治支原体肺炎本身，也可防治由其他疾病导致的支原体肺炎病症。The invention discloses a pharmaceutical composition, which comprises the following raw materials by mass: 1-3 parts of honeysuckle, 1-3 parts of fritillary, 1-3 parts of platycodon grandiflorum, 1-3 parts of Baiqian, 1-3 parts of almond 3 servings, 1~3 servings of Ophiopogon japonicus. The pharmaceutical composition of the present invention can not only prevent and treat mycoplasma pneumonia itself, but also prevent and treat mycoplasma pneumonia caused by other diseases.
Description
Technical Field
The invention relates to the field of pharmaceutical compositions and application methods, in particular to a pharmaceutical composition and an application method.
Background
Mycoplasma pneumonia is a disease which can occur in various animals such as pigs, sheep, cattle and the like, the pathogenesis of the mycoplasma pneumonia is mainly a respiratory disease caused by mycoplasma infection, the main symptoms are respiratory symptoms such as cough, asthma and the like, the lesion is mainly bronchopneumonia, a large amount of researches consider that the disease is an immunosuppressive disease, immunosuppression, obvious reduction of feed reward, even death and elimination and the like are caused in the large-scale livestock breeding production, and the harm is general and serious. But the disease does not infect people and does not pose a direct threat to human health.
Under the conditions of annual immune pressure and improvement of scale culture technology, the disease is chronic and easily recurrent respiratory tract disease, symptoms comprise severe cough, and symptoms and harm are more serious when the disease is secondarily or synergistically infected by cold and other infectious diseases.
For livestock with poor self-regulation ability, such as pigs, cattle, sheep and the like, once infected with the disease, the livestock can generate body temperature rise, then have the phenomena of mental depression and appetite reduction, and the symptoms of cough aggravate after a plurality of days, and can be accompanied with the phenomena of resistance reduction, immunity failure, production achievement reduction and the like caused by immunosuppression. The disease is more serious and the serious livestock with poor immunity or the livestock with poor immunity can die due to the synergistic effect of other diseases.
At present, antibiotic medicaments with obvious curative effects on mycoplasma pneumonia, such as doxycycline, azithromycin, tiamulin and the like, are used for effectively treating the mycoplasma pneumonia, for example, a method for combining the antibiotic and the traditional Chinese medicine is provided in patent 201310538119.X, the antibiotic is combined with a traditional Chinese medicine mixture containing honeysuckle, fritillaria, platycodon grandiflorum, almond and radix ophiopogonis, and the total effective rate of treating the mycoplasma pneumonia is high.
But antibiotic treatment easily generates antibiotic resistance, seriously influences the safety and sanitary quality of animal food and easily causes antibiotic double infection. In addition, besides primary mycoplasma pneumonia, other primary infectious diseases (such as influenza virus, pasteurella infection and streptococcus infection) also show symptoms of mycoplasma pneumonia, the causes of the diseases are complex and difficult to distinguish, and the diseases are still difficult to safely and effectively control by using conventional antibiotic control means.
Disclosure of Invention
The invention aims to provide a pure traditional Chinese medicine composition for domestic animals without antibiotics, which has good prevention and treatment functions on primary mycoplasma pneumonia and diseases caused by other diseases and showing mycoplasma pneumonia symptoms.
Specifically, the invention provides a pharmaceutical composition, which comprises the following raw materials by mass: 1-3 parts of honeysuckle, 1-3 parts of fritillaria, 1-3 parts of platycodon grandiflorum, 1-3 parts of cynanchum glaucescens, 1-3 parts of almond and 1-3 parts of radix ophiopogonis.
The honeysuckle flower in the medicinal composition has the effects of clearing and detoxifying, resisting bacteria and viruses and enhancing the immunological equivalence; the fritillaria has the effects of reducing phlegm and relieving cough, clearing heat and resolving masses, resisting bacteria and diminishing inflammation and the like; the platycodon root is suitable for dispersing lung qi, eliminating phlegm and discharging pus, regulating immunity and the like; bai Qiang is indicated for relieving cough and resolving phlegm, purging lung and relieving asthma, descending qi and checking adverse flow of qi; the almond can relieve cough and asthma, moisten intestine and relieve constipation, resist inflammation and ease pain, etc., and the dwarf lilyturf tuber has the efficacies of nourishing yin and promoting the production of body fluid, moistening lung and clearing heart, diminishing inflammation and relieving constipation, etc. The medicine has the advantages of matching heat-clearing and detoxifying, antibacterial and antiviral effects, resisting inflammation and infection, promoting immune regulation, relieving cough, matching phlegm and eliminating phlegm, increasing phlegm and cough, facilitating the treatment of bronchopneumonia and the overall regulation of an organism, supplementing symptom elimination and pathogeny elimination, promoting the recovery of the bronchopneumonia and preventing the recurrence of the pathogenesis, and achieving the effect of thorough cure.
The raw materials of the invention refer to raw material medicaments for producing the pharmaceutical composition of the invention, can be active ingredients, and can also be carriers (such as traditional Chinese medicines) containing the active ingredients, and the existing forms of the raw materials can be solid, liquid or other forms.
Further, the composition comprises the following raw materials by mass: 1 part of honeysuckle, 1 part of fritillaria, 1 part of platycodon grandiflorum, 1 part of cynanchum glaucescens, 1 part of almond and 1 part of radix ophiopogonis.
Further, the pharmaceutical composition consists of one or more of the following items (1) - (3),
(1) a powder of the raw material;
(2) water extract of the raw materials;
(3) ethanol extract of raw materials.
The pharmaceutical composition can be administered through oral route, for example, can be used as a dressing, and can also be directly drenched.
Further, the particle size of the powder is 100-150 meshes.
Further, the pharmaceutical composition is used for treating mycoplasma pneumonia.
Further, the mycoplasma pneumonia comprises primary mycoplasma pneumonia and other diseases showing mycoplasma pneumonia symptoms.
Further, the pharmaceutical composition is a veterinary pharmaceutical composition.
Further, the pharmaceutical composition is used for treating livestock.
Furthermore, the dosage of the pharmaceutical composition is 20-70 g/day of each raw material.
The pharmaceutical composition of the invention can also be used in combination with one or more of antibiotics, electrolytic multivitamins and yeast tablets, but the effect is inferior compared with the effect of the pharmaceutical composition of the invention used alone.
When in use, the feed can be selected within the application method range according to the weight, health condition and the like of livestock, for example, the feed is taken by each pig or sheep for 20-30 g/day and the feed is taken by each cow for 50-70 g/day in terms of raw materials.
The invention has the beneficial effects that:
(1) the pharmaceutical composition has good treatment effect and anti-infection effect, can balance and condition functions of respiratory system, digestive system, immune system and the like of the affected animals, and controls epidemic spread; can effectively relieve respiratory tract symptoms of livestock and promote physiological function balance improvement; can effectively control bronchopulmonary inflammation, and avoids side effects caused by antibiotic.
(2) According to one embodiment of the invention, the traditional Chinese medicine composition has a good prevention and treatment effect when being used alone, antibiotics are not needed, and hazards such as drug resistance and side effects caused by the large-scale use of the antibiotics are effectively avoided.
(3) The pharmaceutical composition can prevent and treat mycoplasma pneumonia itself, and also can prevent and treat mycoplasma pneumonia diseases caused by other diseases.
Detailed Description
The present invention will be described in further detail with reference to examples, but it should not be construed that the scope of the present invention is limited to the examples. Various substitutions and alterations can be made by those skilled in the art and by conventional means without departing from the spirit of the method of the invention described above.
Example 1
In the last 10 years, hundreds of cases of mycoplasma pneumonia of pigs, sheep or cattle are received and diagnosed in cattle and sheep pig scale farms in provinces such as Sichuan, Hunan, Henan, Shandong, Guangxi and the like, wherein the cases include the affected animals with typical mycoplasma pneumonia symptoms, such as low body temperature or rising, frequent severe cough, growth retardation, irregular population health conditions, obvious reduction of feed reward and the like, and the accompanying symptoms of poor immune effect, cachexia and the like. The mycoplasma pneumonia infection rate in a pig farm site before treatment exceeds 80%, the mycoplasma pneumonia infection rate of a swinery group is different due to different immune conditions, and the infection rate is 10-70%. The infection rate of mycoplasma pneumonia in the sheep farm is more than 90%, the infection rate of the sheep flock is different due to different immunity conditions, and the infection rate is 10-80%. The affected animals infected with mycoplasma pneumonia were treated as follows: taking honeysuckle, fritillaria, platycodon grandiflorum, cynanchum glaucescens, almond and radix ophiopogonis in equal parts by mass, processing the components of the prescription into powder, such as 1 part of honeysuckle, 1 part of fritillaria, 1 part of platycodon grandiflorum, 1 part of cynanchum glaucescens, 1 part of almond and 1 part of radix ophiopogonis, uniformly mixing, sieving by a 100-150-mesh sieve, filling into a clean moisture-proof glass bottle, mixing with a feed for oral administration according to the dose of 20-30 g/day of each pig or sheep and 50-70 g/day of each cow, supplementing measures such as sanitation, disinfection, feeding management enhancement and the like, wherein the average symptom relieving time is 24-30 h, the diseased animals with reduced symptoms show body temperature, the respiratory and digestive functions are gradually normal, the glossiness and the like of inner skin in the symptom relieving period are gradually recovered, the group health degree is; after the mycoplasma pneumonia is insisted for 6-10 days, the respiratory symptoms of the group disappear, and the cure rate is over 90 percent; after the treatment, the mycoplasma pneumonia does not relapse for a long time, and no health difference exists between the original diseased livestock and the healthy livestock after the treatment.
Example 2
Taking the following raw materials in parts by mass: 2.5 parts of honeysuckle, 3 parts of fritillary, 2.5 parts of platycodon grandiflorum, 3 parts of cynanchum glaucescens, 2.5 parts of almond and 3 parts of radix ophiopogonis, mixing, and adding water to extract effective components to obtain a water extract, namely the medicinal composition; the medicinal composition is orally taken to treat the mycoplasma pneumonia according to the dosage of 20-30 g/day for each pig or sheep and 50-70 g/day for each cattle.
Example 3
Taking the following raw materials in parts by mass: 3 parts of honeysuckle, 1.5 parts of fritillary, 3 parts of platycodon grandiflorum, 1.5 parts of cynanchum glaucescens, 3 parts of almond and 1.5 parts of radix ophiopogonis, mixing, and adding ethanol to extract effective components of the mixture to obtain an ethanol extract, namely the medicinal composition, wherein the medicinal composition is orally taken to treat mycoplasma pneumonia according to the dosage of 20-30 g/day of each pig or sheep and 50-70 g/day of each cow on the basis of raw materials.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810240486.4A CN108969648B (en) | 2018-03-22 | 2018-03-22 | Pharmaceutical composition and application method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810240486.4A CN108969648B (en) | 2018-03-22 | 2018-03-22 | Pharmaceutical composition and application method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108969648A CN108969648A (en) | 2018-12-11 |
| CN108969648B true CN108969648B (en) | 2021-05-11 |
Family
ID=64541773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810240486.4A Active CN108969648B (en) | 2018-03-22 | 2018-03-22 | Pharmaceutical composition and application method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108969648B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110339239A (en) * | 2019-08-16 | 2019-10-18 | 郑州赛科药业科技有限公司 | Prevent and treat the Chinese medicine composition and preparation method thereof of contagious bovine pleuropneumonia |
-
2018
- 2018-03-22 CN CN201810240486.4A patent/CN108969648B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| 支原体肺炎中医诊治经验介绍;蔡玲等;《中国乡村医药》;20131130;第20卷(第21期);第34-36页 * |
| 自拟参芪银连汤治疗羊支原体肺炎;张伟;《中兽医医药杂志》;20111231(第02期);第65页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108969648A (en) | 2018-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103006892A (en) | Medicine composition for preventing and treating porcine viral diseases, and premix and batch with composition | |
| CN103230574A (en) | Traditional Chinese medical composition for treating porcine epizootic diarrhea and application thereof | |
| CN102940722B (en) | A kind ofly treat Chinese medicine composition of fowl bacterial disease and preparation method thereof | |
| CN104257794B (en) | Chinese medicine composition of a kind of spleen reinforcing removing food stagnancy and preparation method thereof | |
| CN108969648B (en) | Pharmaceutical composition and application method thereof | |
| CN103127430A (en) | Medicament for treating lower respiratory tract infection and preparation method thereof | |
| CN105688157A (en) | Traditional Chinese medicine compound preparation for resisting swine influenza virus and preparing method thereof | |
| CN101961468B (en) | Traditional Chinese medicinal composition for preventing and treating porcine respiratory syndrome and application thereof | |
| CN104825778A (en) | Traditional Chinese medicine composition for treating calf pneumonia | |
| CN103341154B (en) | Compound veterinary injection for clearing heat and removing toxin | |
| CN107582650A (en) | A kind of Chinese medicine composition for being used to prevent and treat sow mastitis | |
| CN102727693B (en) | Compound propolis composition used for treating swine toxoplasmosis, and preparation method thereof | |
| CN101670005A (en) | Anticoccidiosis pharmaceutical composition and preparation method and use thereof | |
| CN107617018B (en) | Pharmaceutical composition for treating livestock dermatitis herpetiformis and application method thereof | |
| CN101879223A (en) | Chinese medicinal composition for treating livestock and poultry viral diseases and preparation method thereof | |
| CN101376006A (en) | Chinese medicine oral liquid with heat-clearing and detoxicating, cough-suppressing and asthma-relieving functions as well as application thereof for livestock and poultry | |
| CN106334076B (en) | A compound Chinese herbal medicine preparation for preventing and treating chicken infectious laryngotracheitis and its application | |
| CN101664466A (en) | Traditional Chinese herbal composition for treating pyretic pulmonary disease of animals and preparation method thereof | |
| CN101972328A (en) | Chinese medicinal composition for treating sow milk-lacking symptom and preparation method thereof | |
| TWI740228B (en) | Chinese herbal medicine composition for livestock | |
| CN108042690B (en) | Traditional Chinese medicine composition for treating swine mycoplasma pneumonia and application thereof | |
| CN103083414A (en) | Traditional Chinese medicine composition used for enhancing chicken immunity | |
| CN106853024A (en) | Treat Chinese and Western medicine compound oral liquid of grice diarrhoea and preparation method thereof | |
| CN115475205A (en) | Traditional Chinese medicine composition for preventing and treating swine plague and preparation method thereof | |
| CN105031025A (en) | Traditional Chinese medicine compound preparation for treating swine mycoplasmal pneumonia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |